The company's upbeat outlook could allay some
concerns about reimbursement pressures on the sector,
particularly after rival Walgreens Boots Alliance last month
spooked investors by cutting its full-year profit forecast.
Revenue at CVS's pharmacy benefit management unit rose 3.1
percent to $33.56 billion, aided by higher prices of brand name
drugs and also on increased pharmacy claims.
The drugstore chain operator and pharmacy benefits manager said
it earned $1.62 per share excluding items, beating analysts'
average estimate of $1.50 per share, according to IBES data from
Refinitiv.
CVS said it now expects adjusted profit per share of $6.75 to
$6.90 for the full year, compared with its prior forecast of
$6.68 to $6.88.
The company's net income attributable to the company rose to
$1.42 billion, or $1.09 per share, from $998 million, or $0.98
per share, a year earlier.
Revenue rose 34.8 percent to $61.65 billion.
(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb
Chakrabarty)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|